Results 21 to 30 of about 35,107 (301)

Incremental cost-effectiveness ratio (ICER).

, 2021
Incremental cost-effectiveness ratio (ICER).
Christian Auer (4094623), Dachi Arikpo (10661232), Ekperonne Esu (11442197), Angela E. Oyo-Ita (11442188), Patrick Hanlon (11442191), Ogonna Nwankwo (11442194), Martin Meremikwu (558006), Xavier Bosch-Capblanch (176679)   +7 more
core   +1 more source

ICER 2022 Supplemental- ALSO OBSOLETE

, 2022
Supplemental document for ICER 2022 submission ...
Anonymous Anonymous (4854526)
core   +1 more source

Proposed changes ICER 2023 value assessment framework [PDF]

, 2023
Since 2006, the Institute for Clinical and Economic Review (ICER) in the United States has assessed the clinical and economic value of innovative medical technologies and made pricing recommendations with the goal of achieving “sustainable access to ...
A. A. Kurylev, I. R. Svechkareva
core   +1 more source

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US

Cost Effectiveness and Resource Allocation, 2020
Background Patients with infantile-onset spinal muscular atrophy (SMA), a rare, genetic neuromuscular disease, do not achieve key motor function milestones (e.g., sitting) and have short life expectancy in the absence of treatment.
Praveen Thokala, Matt Stevenson, Varun M. Kumar, Shijie Ren, Alexandra G. Ellis, Richard H. Chapman   +5 more
doaj   +1 more source

Tornado diagram-sensitivity of ICER variations.

, 2022
Tornado diagram-sensitivity of ICER variations.
Eskindir Loha (127108), Kjell Arne Johansson (7485632), Bernt Lindtjørn (68598), Solomon H. Tesfaye (13170084)   +3 more
core   +1 more source

A Cost-Effectiveness Analysis of AcrySof IQ Vivity Intraocular Lens (IOL) from Private Health Fund Perspective in Australia

Clinical Ophthalmology, 2022
Chandra Bala,1 Paul Athanasiov,2 Jason Holland,3 Mukesh Dhariwal,4 Amit Gupta,5 Hemant Rathi6 1personalEYES Pty Ltd, Sydney, NSW, Australia; 2Eye Surgeons SA, North Adelaide, SA, Australia; 3The Eye Health Centre, Brisbane, QLD, Australia; 4Alcon Vision ...
Bala C, Athanasiov P, Holland J, Dhariwal M, Gupta A, Rathi H   +5 more
doaj  

International experience in determining the cost-effectiveness thresholds

Фармакоэкономика, 2019
The article reviews international methodological guidelines, regulatory documents and existing approaches to the determination of the costeffectiveness threshold (CeT), also known as the willingness-to-pay threshold (WTP), the threshold value of the ...
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky   +5 more
doaj   +1 more source

Differences in ICER/QALY, ICER/LY and ICER/DALY with vs. without Herd protection^*.

, 2017
Differences in ICER/QALY, ICER/LY and ICER/DALY with vs. without Herd protection*.
John P. A. Ioannidis (51405), Marisa Holubar (3804844), Maria Christina Stavroulakis (3804841), Yvonne Maldonado (395050), Despina Contopoulos-Ioannidis (3752740)   +4 more
core   +1 more source

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy

ClinicoEconomics and Outcomes Research, 2021
Gianni Ghetti,1 Maria Claudia D’Avella,2 Lorenzo Pradelli1 1Department of Health Economics and Outcome Research, AdRes, Turin, Italy; 2Department of Market Access, Sanofi, Milan, ItalyCorrespondence: Gianni GhettiDepartment of Health Economics and ...
Ghetti G, D'Avella MC, Pradelli L
doaj  

THE ECONOMIC RATIONALE FOR THE USE OF OUTPATIENT PLEURODESIS IN THE TREATMENT OF MALIGNANT PLEURAL EFFUSIONS

Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2020
Introduction. Exudative tumor pleurisy affects up to 100 000 people a year in Russia, up to 400 000 people a year in Europe. Inpatient treatment of such patients is associated with certain costs, and there are also queues for treatment in oncology ...
O. V. Ivanov, V. N. Klimenko, A. V. Reshetov   +2 more
doaj   +1 more source